Latest news
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It - FinancialContentFinancialContent · Thu, 06 Aug 2026 13:40:00 GMTRhythm Pharmaceuticals' RM-718 shows positive Phase 2 signal in acquired hypothalamic obesity - DealroomDealroom · Wed, 05 Aug 2026 08:01:44 GMTRM-718 shows 11.6% BMI reduction in acquired hypothalamic obesity trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Wed, 05 Aug 2026 07:37:44 GMTRhythm Pharmaceuticals Announces Preliminary Data from - GlobeNewswireGlobeNewswire · Tue, 04 Aug 2026 10:55:00 GMTSetmelanotide Linked With Reduced BMI and Hunger in Patients With Acquired Hypothalamic Obesity - Docwire NewsDocwire News · Mon, 03 Aug 2026 15:52:50 GMTSetmelanotide Beneficial in Acquired Hypothalamic Obesity - Endocrinology AdvisorEndocrinology Advisor · Mon, 27 Jul 2026 04:00:00 GMT